Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction
Status: Enrolling
Updated:  2/1/2013
Center for Digestive Health
mi
from
Troy, MI
Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction
Status: Enrolling
Updated: 2/1/2013
Center for Digestive Health
mi
from
Troy, MI
Click here to add this to my saved trials
Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction
Status: Enrolling
Updated:  2/1/2013
Montana Neuroscience Institute Foundation / Montana Spine and Pain Center
mi
from
Missoula, MT
Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction
Status: Enrolling
Updated: 2/1/2013
Montana Neuroscience Institute Foundation / Montana Spine and Pain Center
mi
from
Missoula, MT
Click here to add this to my saved trials
Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction
Status: Enrolling
Updated:  2/1/2013
The Office of Dr. Stephen H. Miller, MD
mi
from
Las Vegas, NV
Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction
Status: Enrolling
Updated: 2/1/2013
The Office of Dr. Stephen H. Miller, MD
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction
Status: Enrolling
Updated:  2/1/2013
Long Island Gastrointestinal Research Group
mi
from
Great Neck, NY
Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction
Status: Enrolling
Updated: 2/1/2013
Long Island Gastrointestinal Research Group
mi
from
Great Neck, NY
Click here to add this to my saved trials
Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction
Status: Enrolling
Updated:  2/1/2013
COR Clinical Research
mi
from
Oklahoma City, OK
Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction
Status: Enrolling
Updated: 2/1/2013
COR Clinical Research
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction
Status: Enrolling
Updated:  2/1/2013
Memorial Clinical Research
mi
from
Oklahoma City, OK
Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction
Status: Enrolling
Updated: 2/1/2013
Memorial Clinical Research
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction
Status: Enrolling
Updated:  2/1/2013
Medford Medical Clinic, LLP
mi
from
Medford, OR
Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction
Status: Enrolling
Updated: 2/1/2013
Medford Medical Clinic, LLP
mi
from
Medford, OR
Click here to add this to my saved trials
Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction
Status: Enrolling
Updated:  2/1/2013
Trident Institute of Medical Research, LLC
mi
from
North Charleston, SC
Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction
Status: Enrolling
Updated: 2/1/2013
Trident Institute of Medical Research, LLC
mi
from
North Charleston, SC
Click here to add this to my saved trials
Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction
Status: Enrolling
Updated:  2/1/2013
Southeastern Clinical Research
mi
from
Chattanooga, TN
Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction
Status: Enrolling
Updated: 2/1/2013
Southeastern Clinical Research
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction
Status: Enrolling
Updated:  2/1/2013
Comprehensive Pain Specialists
mi
from
Hendersonville, TN
Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction
Status: Enrolling
Updated: 2/1/2013
Comprehensive Pain Specialists
mi
from
Hendersonville, TN
Click here to add this to my saved trials
Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction
Status: Enrolling
Updated:  2/1/2013
New River Valley Research Institute
mi
from
Christianburg, VA
Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction
Status: Enrolling
Updated: 2/1/2013
New River Valley Research Institute
mi
from
Christianburg, VA
Click here to add this to my saved trials
Improving Effective Contraceptive Use Among Opioid-maintained Women
Improving Effective Contraceptive Use Among Opioid-maintained Women
Status: Enrolling
Updated:  2/5/2013
University of Vermont Substance Abuse Treatment Center
mi
from
Burlington, VT
Improving Effective Contraceptive Use Among Opioid-maintained Women
Improving Effective Contraceptive Use Among Opioid-maintained Women
Status: Enrolling
Updated: 2/5/2013
University of Vermont Substance Abuse Treatment Center
mi
from
Burlington, VT
Click here to add this to my saved trials
Radius Loading in Primary Hyperparathyroidism
Effect of Mechanical Loading on Radius Bone Density and Microarchitecture in Primary Hyperparathyroidism
Status: Enrolling
Updated:  2/12/2013
Columbia University Medical Center
mi
from
New York, NY
Radius Loading in Primary Hyperparathyroidism
Effect of Mechanical Loading on Radius Bone Density and Microarchitecture in Primary Hyperparathyroidism
Status: Enrolling
Updated: 2/12/2013
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  2/13/2013
Pfizer Investigational Site
mi
from
Alabaster, AL
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 2/13/2013
Pfizer Investigational Site
mi
from
Alabaster, AL
Click here to add this to my saved trials
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  2/13/2013
Pfizer Investigational Site
mi
from
Gilbert, AZ
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 2/13/2013
Pfizer Investigational Site
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  2/13/2013
Pfizer Investigational Site
mi
from
Los Angeles, CA
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 2/13/2013
Pfizer Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  2/13/2013
Pfizer Investigational Site
mi
from
Bridgeport, CT
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 2/13/2013
Pfizer Investigational Site
mi
from
Bridgeport, CT
Click here to add this to my saved trials
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  2/13/2013
Pfizer Investigational Site
mi
from
Atlantis, FL
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 2/13/2013
Pfizer Investigational Site
mi
from
Atlantis, FL
Click here to add this to my saved trials
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  2/13/2013
Pfizer Investigational Site
mi
from
Atlanta, GA
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 2/13/2013
Pfizer Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  2/13/2013
Pfizer Investigational Site
mi
from
Biloxi, MS
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 2/13/2013
Pfizer Investigational Site
mi
from
Biloxi, MS
Click here to add this to my saved trials
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  2/13/2013
Pfizer Investigational Site
mi
from
Rochester, NY
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 2/13/2013
Pfizer Investigational Site
mi
from
Rochester, NY
Click here to add this to my saved trials
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  2/13/2013
Pfizer Investigational Site
mi
from
Asheville, NC
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 2/13/2013
Pfizer Investigational Site
mi
from
Asheville, NC
Click here to add this to my saved trials
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  2/13/2013
Pfizer Investigational Site
mi
from
Akron, OH
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 2/13/2013
Pfizer Investigational Site
mi
from
Akron, OH
Click here to add this to my saved trials
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  2/13/2013
Pfizer Investigational Site
mi
from
Norman, OK
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 2/13/2013
Pfizer Investigational Site
mi
from
Norman, OK
Click here to add this to my saved trials
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  2/13/2013
Pfizer Investigational Site
mi
from
Bristol, TN
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 2/13/2013
Pfizer Investigational Site
mi
from
Bristol, TN
Click here to add this to my saved trials
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  2/13/2013
Pfizer Investigational Site
mi
from
Houston, TX
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 2/13/2013
Pfizer Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  2/13/2013
Pfizer Investigational Site
mi
from
West Jordan, UT
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 2/13/2013
Pfizer Investigational Site
mi
from
West Jordan, UT
Click here to add this to my saved trials
Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light
Prospective, Randomized, Controlled, Partially Blinded, Skin Photobiological Clinical Study of the Efficacy and Safety of a Sunscreen Product as Skin Protector Against Porfimer Sodium-induced Phototoxicity to Visible Light
Status: Enrolling
Updated:  2/18/2013
St. Mary's Hospital - Mayo Clinic
mi
from
Rochester, MN
Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light
Prospective, Randomized, Controlled, Partially Blinded, Skin Photobiological Clinical Study of the Efficacy and Safety of a Sunscreen Product as Skin Protector Against Porfimer Sodium-induced Phototoxicity to Visible Light
Status: Enrolling
Updated: 2/18/2013
St. Mary's Hospital - Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light
Prospective, Randomized, Controlled, Partially Blinded, Skin Photobiological Clinical Study of the Efficacy and Safety of a Sunscreen Product as Skin Protector Against Porfimer Sodium-induced Phototoxicity to Visible Light
Status: Enrolling
Updated:  2/18/2013
Ohio State University
mi
from
Columbus, OH
Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light
Prospective, Randomized, Controlled, Partially Blinded, Skin Photobiological Clinical Study of the Efficacy and Safety of a Sunscreen Product as Skin Protector Against Porfimer Sodium-induced Phototoxicity to Visible Light
Status: Enrolling
Updated: 2/18/2013
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Ghrelin and Gastric Emptying in Children With Functional Dyspepsia
Evaluation of Liquid Gastric Emptying and Plasma Ghrelin in Children With Functional Dyspepsia
Status: Enrolling
Updated:  2/19/2013
Children's Mercy Hospital
mi
from
Kansas City, MO
Ghrelin and Gastric Emptying in Children With Functional Dyspepsia
Evaluation of Liquid Gastric Emptying and Plasma Ghrelin in Children With Functional Dyspepsia
Status: Enrolling
Updated: 2/19/2013
Children's Mercy Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
Nutrition, Exercise, and Breast Cancer Survivorship
Impact of Nutrition and Exercise on Glucose Metabolism, Inflammation, and Body Composition in Older Breast Cancer Survivors
Status: Enrolling
Updated:  2/21/2013
Baltimore VAMC
mi
from
Baltimore, MD
Nutrition, Exercise, and Breast Cancer Survivorship
Impact of Nutrition and Exercise on Glucose Metabolism, Inflammation, and Body Composition in Older Breast Cancer Survivors
Status: Enrolling
Updated: 2/21/2013
Baltimore VAMC
mi
from
Baltimore, MD
Click here to add this to my saved trials
Standard Versus Mnemonic Counseling for Fecal Incontinence
Standard Versus Mnemonic Counseling for Fecal Incontinence: a Pilot Randomised Control Trial
Status: Enrolling
Updated:  2/21/2013
University of New Mexico
mi
from
Albuquerque, NM
Standard Versus Mnemonic Counseling for Fecal Incontinence
Standard Versus Mnemonic Counseling for Fecal Incontinence: a Pilot Randomised Control Trial
Status: Enrolling
Updated: 2/21/2013
University of New Mexico
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Visions Clinical Research - Tucson
mi
from
Tucson, AZ
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Visions Clinical Research - Tucson
mi
from
Tucson, AZ
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Preferred Research Partners, Inc.
mi
from
Little Rock, AR
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Preferred Research Partners, Inc.
mi
from
Little Rock, AR
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Lynn Institue of the Ozarks
mi
from
Little Rock, AR
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Lynn Institue of the Ozarks
mi
from
Little Rock, AR
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Rokay Kamyar, MD Inc
mi
from
La Mesa, CA
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Rokay Kamyar, MD Inc
mi
from
La Mesa, CA
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Medvin Clinical Research
mi
from
Covina, CA
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Medvin Clinical Research
mi
from
Covina, CA
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Lakewood Primary Care Medical Group, Inc.
mi
from
Lakewood, CA
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Lakewood Primary Care Medical Group, Inc.
mi
from
Lakewood, CA
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Collaborative Neuroscience Network, Inc.
mi
from
Long Beach, CA
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Collaborative Neuroscience Network, Inc.
mi
from
Long Beach, CA
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Alliance Research
mi
from
Long Beach, CA
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Alliance Research
mi
from
Long Beach, CA
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Alliance Clinical Research, LLC
mi
from
Poway, CA
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Alliance Clinical Research, LLC
mi
from
Poway, CA
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Digestive Care Associates
mi
from
San Carlos, CA
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Digestive Care Associates
mi
from
San Carlos, CA
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
San Diego Clinical Trials
mi
from
San Diego, CA
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
San Diego Clinical Trials
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Gastroenterology of the Rockies
mi
from
Lafayette, CO
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Gastroenterology of the Rockies
mi
from
Lafayette, CO
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Sanitas Research
mi
from
Coral Gables, FL
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Sanitas Research
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Avail Clinical Research
mi
from
DeLand, FL
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Avail Clinical Research
mi
from
DeLand, FL
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Florida Medical Research Institute
mi
from
Gainesville, FL
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Florida Medical Research Institute
mi
from
Gainesville, FL
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Center for Gastrointestinal Disorders
mi
from
Hollywood, FL
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Center for Gastrointestinal Disorders
mi
from
Hollywood, FL
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Borland-Groover Clinic
mi
from
Jacksonville, FL
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Borland-Groover Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials